David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 10,818 shares at $294.03 ($3.2M) on 2023-02-21, disclosed to the SEC on 2023-02-22.
Seasonal sale ($3.2M) by EVP, Global Research and CSO — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $292.85 | 3,750 | $1.1M | 34.6% |
| 2 | $291.01 | 36 | $10K | 0.3% |
| 3 | $292.76 | 1,223 | $358K | 11.3% |
| 4 | $292.76 | 1,223 | $358K | 11.3% |
| 5 | $294.03 | 1,843 | $542K | 17.1% |
| 6 | $294.03 | 1,843 |
| $542K |
| 17.1% |
| 7 | $294.73 | 900 | $265K | 8.4% |
| Total | $293.38 avg | 10,818 | $3.2M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |